Foundation Medicine to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., February 7, 2013 - Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that members of the company's management team will present at the following upcoming investor conferences:
- 2013 Leerink Swann Global Healthcare Conference, February 13-14, 2013 in New York City
- Citi 2013 Global Healthcare Conference, February 25-27, 2013 in New York City
- Cowen 33rd Annual Healthcare Conference, March 4-6, 2013 in Boston
About Foundation Medicine
Foundation Medicine®, is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's initial clinical assay, FoundationOne™, is a fully informative genomic profile to identify a patient's individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark of Foundation Medicine, Inc.
Pure Communications, Inc.